Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~7.5 days
Time for 50 % to be eliminated
Steady State
~32.4 days
≈ 4.3 half-lives
Accumulation
×11.3
Cmax at steady state ÷ Cmax first dose
Gone After
~52.5 days
after last dose
Source: Enebo et al., Lancet 2021 (159–195 h; semaglutide co-administration). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Cagrilintide: ~8 days.
A phase 1b co-administration study reported a cagrilintide half-life range of 159 to 195 hours; the calculator uses 180 hours as a transparent midpoint scalar.
The 180-hour value lies within the published range but is not a separate measurement or a universal constant. It must remain tied to the study design and combination context.
Enebo et al., Lancet 2021: reported cagrilintide half-life range of 159 to 195 hours.
Cagrilintide is a synthetic amylin analogue created through a peptide structure-activity development program. The primary medicinal-chemistry publication describes it as stable, lipidated and long acting. Lipidation is part of the molecular design used to extend exposure compared with short-lived native peptide signaling, while sequence and structural choices were evaluated to retain the intended pharmacological profile. These design characteristics define the compound for research purposes; they do not make a research vial a pharmaceutical product.
This product contains 5 mg of lyophilized cagrilintide research material in a sealed vial. The stated mass identifies the supplied format and is not a recommendation for administration. Cagrilintide remains an investigational compound, and this material is offered for controlled laboratory work such as analytical method development, receptor-focused research or appropriately designed experimental models. It is not represented as equivalent to material used in a clinical trial.
For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, prevention or consumption. No clinical equivalence, suitability for administration or therapeutic performance is represented.